Navigation Links
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
Date:5/21/2009

tive ideas, products and services to advance the health and well-being of people. Our approximately 119,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

About Ortho Biotech Oncology Research & Development

Ortho Biotech Oncology Research & Development, a unit of Centocor Research & Development, Inc., a Johnson & Johnson company, is a research and development organization dedicated to oncology, hematology and supportive care. It partners closely with Centocor Ortho Biotech Products, L.P. and Janssen-Cilag companies worldwide to bring oncology treatments and supportive medicines to patients around the world.

About Cougar Biotechnology, Inc.

Cougar Biotechnology is a Los Angeles-based biotechnology company, established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar Biotechnology's oncology portfolio includes abiraterone acetate (CB7630), an orally available targeted inhibitor of the steroidal enzyme known as 17-alpha hydroxylase/C17,20 lyase, which is currently being studied in two Phase III clinical trials in prostate cancer and a Phase I/II trial in breast cancer; noscapine (CB3304), an inhibitor of microtubule dynamics, which is currently in a Phase I trial in multiple myeloma; and seocalcitol (CB1089), an analog of vitamin D, which has been clinically tested in a number of solid tumor types. Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurat
'/>"/>

SOURCE Johnson & Johnson
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Simbionix and Johnson & Johnson LLC Announce a Distribution Agreement for Russia and the CIS Countries
2. Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
3. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
4. Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
5. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
6. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
7. Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production
8. Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research
9. Migenix averts proxy contest; reaches agreement with DJohnson holdings
10. Craig Johnson Joins Ardea Biosciences Board of Directors
11. Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BEIJING , Dec. 23, 2014 ... or the "Company"), a leading fully integrated plasma-based ... today announced that its majority-owned subsidiary, Shandong Taibang ... Practices ("GMP") certification from the China Food and ... factor production facility. As previously disclosed in the ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
(Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Wis. - For the second time this year, a ... stock for sale to the public. Called an initial public ... to the companies and investors who are directly involved, but ... NimbleGen , a Madison-based biotechnology company, has filed papers with ...
... to experience high rates of failure. As a result, ... valued partner. The result stifles innovation, growth, and a ... requires shedding the flawed processes of yesterday, and introducing ... by promising incremental delivery of functional software. , , ...
... - Now that two companies he once owned ... strategy, Brian Wiegand's days as a self-described serial entrepreneur ... NameProtect , a developer of digital brand management ... of Wilmington, Del. , ,He will concentrate on ...
Cached Biology Technology:Wisconsin IPOs are a harbinger of growing tech economy 2Wisconsin IPOs are a harbinger of growing tech economy 3Agile Revolution: A new era of software delivery 2Agile Revolution: A new era of software delivery 3Agile Revolution: A new era of software delivery 4NameProtect sold, tech entrepreneur to focus on Jellyfish.com 2
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... 20, 2010 TEL AVIV, Israel - European business ... leading platform for R&D-performing entrepreneurs and industries, will gather ... to take part in the first event in Israel ... Israel at the reigns of the EUREKA Network and ...
... and first use of a high-density SNP array for ... capable of revealing new insights into how the insect ... to findings published in the current edition of the ... the Anopheles gambiae genome can be used ...
... A child,s chances of developing allergies or wheezing is ... in the womb, according to scientists from the University of ... Research Council (MRC) and the British Lung Foundation, and undertaken ... in early pregnancy but falter later in pregnancy are likely ...
Cached Biology News:Israeli Minister of Industry and Trade to address European R&D leaders in Tel Aviv 2Genetic markers offer new clues about how malaria mosquitoes evade eradication 2Genetic markers offer new clues about how malaria mosquitoes evade eradication 3Allergies and wheezing illnesses in childhood may be determined in the womb 2
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer...
...
Request Info...
Request Info...
Biology Products: